Seeberger’s group utilized the carbohydrate synthesizer to develop a malaria vaccine. Medical trials for the vaccine are scheduled for 2010 2010 in Mozambique and Tanzania. Its unique anti-disease system makes it the only vaccine of its kind, he says. To my knowledge, ours may be the 1st attempt at an anti-disease vaccine. It generally does not actually eliminate the malarial parasite; it blocks its toxic actions. You create antibodies against the glucose structure, and these antibodies block the carbohydrate toxin from resulting in anemia and inflammation, the hallmarks of malarial contamination, says Seeberger.In this double-blind trial, 2 percent AN2728 ointment or vehicle ointment was used twice daily for a week to 10 percent body surface area in a single cohort and 35 percent BSA in another. No serious or severe adverse events were observed no clinically meaningful laboratory or ECG abnormalities were found. Pharmacokinetic profiles showed suprisingly low systemic exposure. In conclusion, the trial demonstrated that 2 percent AN2728 topical ointment was well-tolerated and offered a substantial margin of security for both acute and chronic effects when applied twice daily to healthy volunteers. ‘AN2728 has reached its essential endpoints in the seven scientific trials we have conducted thus far,’ said David Perry, Chief Executive Officer of Anacor Pharmaceuticals.